Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel
Pasculli, Barbara (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia)
Barbano, Raffaela (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia)
Rendina, M. (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia)
Fontana, Andrea (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Biostatistica)
Copetti, Massimiliano (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Biostatistica)
Mazza, T. (Fondazione IRCCS Casa Sollievo della Sofferenza. Bioinformatics Unit)
Valori, V. M. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Oncologia)
Morritti, M. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Oncologia)
Maiello, Evaristo (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Oncologia)
Graziano, Paolo (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Anatomia Patologica)
Murgo, R. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Chirurgia Senologica)
Fazio, V. M. (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia)
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Parrella, Paola (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	MicroRNA-210-3p is the most prominent hypoxia regulated microRNA, and it has been found significantly overexpressed in different human cancers. We performed the expression analysis of miR-210-3p in a retrospective cohort of breast cancer patients with a median follow-up of 76 months (n = 283). An association between higher levels of miR-210-3p and risk of disease progression (HR: 2. 13, 95%CI: 1. 33-3. 39, P = 0. 002) was found in the subgroup of patients treated with Epirubicin and Cyclophosphamide followed by Docetaxel. Moreover, a cut off value of 20. 966 established by ROC curve analyses allowed to discriminate patients who developed distant metastases with an accuracy of 85% at 3- (AUC: 0. 870, 95%CI: 0. 690-1. 000) and 83% at 5-years follow up (AUC: 0. 832, 95%CI: 0. 656-1. 000). Whereas the accuracy in discriminating patients who died for the disease was of 79. 6% at both 5- (AUC: 0. 804, 95%CI: 0. 517-1. 000) and 10-years (AUC: 0. 804. 95%CI: 0. 517-1. 000) follow-up. In silico analysis of miR-210-3p and Docetaxel targets provided evidence for a putative molecular cross-talk involving microtubule regulation, drug efflux metabolism and oxidative stress response. Overall, our data point to the miR-210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Breast cancer ; MiRNAs ; Predictive markers
Published in:	Scientific reports, Vol. 9 Núm. 1 (january 2019) , p. 14913, ISSN 2045-2322

DOI: 10.1038/s41598-019-51581-3
PMID: 31624308

9 p, 2.0 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles